Weight acquire after stopping Eli Lilly’s new weight problems remedy ought to assist, not harm the inventory

David Ricks, CEO, Eli Lilly

Scott Mlyn | CNBC

Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell.

Comments are closed.